Pharmaceutical benefits scheme (pbs): listings for remicade
REMICADE is PBS-listed as a Section 100 item for the treatment of Crohn’s Disease and ulcerative colitis.
For more information on PBS eligibility criteria, please refer to individual indications.
GENERAL INFORMATION FOR PRESCRIBERS
To ensure patient eligibility for PBS-subsidised REMICADE, the prescribing doctor must:
- Record evidence that the patient meets the PBS criteria in the patients’ medical notes
- Be in receipt of a signed patient acknowledgement form indicating they understand and acknowledge that PBS subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing treatment as outlined under restrictions for continuing treatment.
Quick guide to PBS-subsidised REMICADE for ulcerative colitis
ESR, erythrocyte sedimentation rate; PUCAI, Paediatric Ulcerative Colitis Activity Index.
Quick guide to PBS-subsidised REMICADE for Crohn’s disease
CDAI, Crohn’s Disease Activity Index; PCDAI, Paediatric Crohn’s Disease Activity Index; TPN, total parenteral nutrition.
For more information, please refer to the PBS website.
Please refer to Product Information before prescribing. Full product Information is available here. Further information is available on request from Janssen.
PBS INFORMATION: This product is listed as a Section 100 item for Crohn's disease and ulcerative colitis. Refer to PBS Schedule for full authority information.